芬太尼透皮贴剂与盐酸羟考酮缓释片治疗中度癌性疼痛的效果比较  

Comparison of the Efficacy of Fentanyl Transdermal Patch and Oxycodone Hydrochloride Sustained-Release Tablets in the Treatment of Moderate Cancer Pain

作　　者：宋洁 黄钰涵 张鑫君 Song Jie;Huang Yuhan;Zhang Xinjun(Department of Pharmacy,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu Province,China;Department of Radiation Oncology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,Jiangsu Province,China)

机构地区：[1]徐州医科大学附属医院药学部,江苏徐州221000 [2]徐州医科大学附属医院肿瘤放疗科,江苏徐州221000

出　　处：《中外医药研究》2025年第4期21-23,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:比较芬太尼透皮贴剂与盐酸羟考酮缓释片治疗中度癌性疼痛的效果。方法:选取2021年2月—2023年2月徐州医科大学附属医院收治的90例中度癌性疼痛患者为研究对象,依据随机数字表法分为对照组与观察组,各45例。对照组采用盐酸羟考酮缓释片治疗,观察组采用芬太尼透皮贴剂治疗。对比两组疼痛程度、生存状态、睡眠质量、应激反应及不良反应发生率。结果:治疗前,两组数字评价量表(NRS)评分、卡氏行为状态评分(KPS)、匹兹堡睡眠质量指数(PSQI)评分对比,无统计学差异(P>0.05)。治疗后,两组NRS、PSQI评分降低,KPS升高,观察组PSQI评分低于对照组,KPS高于对照组(P<0.05);两组NRS评分比较,差异无统计学意义(P>0.05)。治疗前,两组5-羟色胺(5-HT)、P物质(SP)、前列腺素E_(2)(PGE_(2))、血清β-内啡肽(β-EP)水平对比,无统计学差异(P>0.05);治疗后,两组5-HT、SP、PGE_(2)水平降低,β-EP水平升高,观察组优于对照组(P<0.05)。观察组不良反应总发生率低于对照组(P=0.011)。结论:芬太尼透皮贴剂与盐酸羟考酮缓释片均可减轻中度癌性疼痛,但是芬太尼透皮贴剂可进一步减轻患者的应激反应,改善其生存状态和睡眠质量,且不良反应发生率更低。Objective:To compare the efficacy of fentanyl transdermal patch and oxycodone hydrochloride sustained-release tablets in the treatment of moderate cancer pain.Methods:A total of 90 patients with moderate cancer pain admitted to the Affiliated Hospital of Xuzhou Medical University from February 2021 to February 2023 were selected as the study subjects.They were divided into a control group and an observation group using a random number table,with 45 patients in each group.The control group was treated with oxycodone hydrochloride sustained-release tablets,while the observation group was treated with fentanyl transdermal patch.The pain intensity,survival status,sleep quality,stress response,and incidence of adverse reactions were compared between the two groups.Results:Before treatment,there were no statistically significant differences in the Numerical Rating Scale(NRS)score,Karnofsky Performance Status(KPS)score,or Pittsburgh Sleep Quality Index(PSQI)score between the two groups(P>0.05).After treatment,both groups showed decreased NRS and PSQI scores and increased KPS scores.The PSQI score in the observation group was lower,and the KPS score was higher than those in the control group(P<0.05).There was no significant difference in NRS scores between the two groups(P>0.05).Before treatment,there were no significant differences in the levels of 5-hydroxytryptamine(5-HT),substance P(SP),prostaglandin E_(2)(PGE_(2)),or serumβ-endorphin(β-EP)between the two groups(P>0.05).After treatment,both groups showed decreased levels of 5-HT,SP,and PGE_(2) and increased levels ofβ-EP,with the observation group outperforming the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P=0.011).Conclusion:Both fentanyl transdermal patch and oxycodone hydrochloride sustained-release tablets can alleviate moderate cancer pain.However,fentanyl transdermal patch further reduces stress response,improves survival status and sleep quality,and has a lower incidence

关 键 词：癌性疼痛 芬太尼透皮贴剂 盐酸羟考酮缓释片 

分 类 号：R730.5[医药卫生—肿瘤]